Mirela Cerghet

This study identifies treatment-specific miRNA response signatures in RRMS patients following cladribine or ocrelizumab, revealing distinct molecular programs associated with each therapy.

This study uses untargeted metabolomics to identify altered serum metabolites distinguishing relapsing-remitting MS, progressive MS, and healthy subjects.

The paper identifies altered omega fatty acid-derived lipid mediators in RRMS patients using metabolipidomics, suggesting their potential as biomarkers for diagnosis and prognosis.

This study shows that MaR1 treatment reduces inflammation, protects neurons, and improves metabolism in a mouse model of multiple sclerosis.

The paper identifies altered metabolic pathways in RRMS patients using metabolomics and shows that targeting glycolysis can reduce disease progression in a mouse model.